Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule

Lynn G Feun, Niramol Savaraj, G. P. Bodey, K. Lu, B. S. Yap, J. A. Ajani, M. A. Burgess, R. S. Benjamin, E. McKelvey, I. Krakoff

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-β-D-ribo furanosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day x 5 days to 40 mg/sq m/day x 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.

Original languageEnglish
Pages (from-to)3608-3612
Number of pages5
JournalCancer Research
Volume44
Issue number8
StatePublished - Sep 27 1984
Externally publishedYes

Fingerprint

Nucleosides
Appointments and Schedules
Phosphates
triciribine phosphate
Tonsillar Neoplasms
Hyperamylasemia
Neoplasm Metastasis
Squamous Cell Neoplasms
Stomatitis
Hypertriglyceridemia
Mesothelioma
Thyroid Neoplasms
Sarcoma
Hyperglycemia
Thrombocytopenia
Colonic Neoplasms
Phosphorus
Nausea
Vomiting
Anemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feun, L. G., Savaraj, N., Bodey, G. P., Lu, K., Yap, B. S., Ajani, J. A., ... Krakoff, I. (1984). Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Research, 44(8), 3608-3612.

Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. / Feun, Lynn G; Savaraj, Niramol; Bodey, G. P.; Lu, K.; Yap, B. S.; Ajani, J. A.; Burgess, M. A.; Benjamin, R. S.; McKelvey, E.; Krakoff, I.

In: Cancer Research, Vol. 44, No. 8, 27.09.1984, p. 3608-3612.

Research output: Contribution to journalArticle

Feun, LG, Savaraj, N, Bodey, GP, Lu, K, Yap, BS, Ajani, JA, Burgess, MA, Benjamin, RS, McKelvey, E & Krakoff, I 1984, 'Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule', Cancer Research, vol. 44, no. 8, pp. 3608-3612.
Feun, Lynn G ; Savaraj, Niramol ; Bodey, G. P. ; Lu, K. ; Yap, B. S. ; Ajani, J. A. ; Burgess, M. A. ; Benjamin, R. S. ; McKelvey, E. ; Krakoff, I. / Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. In: Cancer Research. 1984 ; Vol. 44, No. 8. pp. 3608-3612.
@article{6eb5d994b78a42469ac976f90f489967,
title = "Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule",
abstract = "A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-β-D-ribo furanosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day x 5 days to 40 mg/sq m/day x 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.",
author = "Feun, {Lynn G} and Niramol Savaraj and Bodey, {G. P.} and K. Lu and Yap, {B. S.} and Ajani, {J. A.} and Burgess, {M. A.} and Benjamin, {R. S.} and E. McKelvey and I. Krakoff",
year = "1984",
month = "9",
day = "27",
language = "English",
volume = "44",
pages = "3608--3612",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule

AU - Feun, Lynn G

AU - Savaraj, Niramol

AU - Bodey, G. P.

AU - Lu, K.

AU - Yap, B. S.

AU - Ajani, J. A.

AU - Burgess, M. A.

AU - Benjamin, R. S.

AU - McKelvey, E.

AU - Krakoff, I.

PY - 1984/9/27

Y1 - 1984/9/27

N2 - A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-β-D-ribo furanosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day x 5 days to 40 mg/sq m/day x 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.

AB - A Phase I trial of tricyclic nucleoside phosphate (1,4,5,6,8-pentaazaacenaphthylene-3-amino-1,5-dihydro-5-methyl-1-β-D-ribo furanosyl 5'-phosphate ester; NSC 280594) was conducted using a 5-day continuous infusion schedule. Thirty-seven patients with advanced cancer were entered on the study, of whom 33 patients were evaluable for response and toxicity. Dose levels ranged from 10 mg/sq m/day x 5 days to 40 mg/sq m/day x 5 days. Initially, courses were repeated every 3 to 4 weeks. As cumulative toxicity became manifested, the interval between courses was changed to every 6 weeks. Major toxicities included hyperglycemia, hepatotoxicity, and thrombocytopenia. Patients with a prior history of diabetes mellitus, extensive radiation therapy, or significant liver metastases were prone to severe toxicity. Other toxicities noted were nausea and vomiting, abdominal discomfort, anemia, and reduction in serum calcium, phosphorus, and albumin levels. Rare side effects included hypertriglyceridemia, hyperamylasemia, diarrhea, and stomatitis. Antitumor activity observed include improvement in s.c. metastases in a patient with thyroid carcinoma, stabilization of disease in a patient with mesothelioma, and mixed responses in three patients (colon cancer, sarcoma, and tonsillar squamous cell cancer). Recommended schedule for Phase II studies is 20 mg/sq m/day for 5 days every 6 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0021215741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021215741&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 3608

EP - 3612

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -